Clinical trials: Type 2 Diabetes Risk
Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis
An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol
This clinical study was designed to assess the efficacy, safety, and tolerability of long-term dosing of inclisiran and evolocumab given as subcutaneous injections in participants with high cardiovascular risk and elevated…
- Conditions
- Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis, Type2 Diabetes, Familial Hypercholesterolemia
- Trial name
- ORION-3 (NCT03060577)
- Testing
- Inclisiran, Evolocumab
- Where
- 52 sites in United States, Canada and 3 more
- Volunteers
- 382 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Treated With Insulin, Hypoglycemia
Reducing Treatment Risk in Older Adults With Diabetes
This study will evaluate the impact of academic detailing (evidence-based provider education) with or without patient pre-visit preparation (elicitation of values and preferences) on safe insulin de-prescribing among older…
- Conditions
- Type 2 Diabetes Treated With Insulin, Hypoglycemia, Primary Health Care, Polypharmacy
- Trial name
- RETRO-DM (NCT04585191)
- Testing
- Conversation Aid, Attention Control Educational Handout
- Where
- 4 sites in United States
- Volunteers
- 450 people
- Sponsor
- Kaiser Permanente
Diabetes Mellitus, Type 2
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
The aim of the study is to investigate the longterm impact on cardiovascular morbidity and mortality, relevant efficacy parameters (e.g., glycaemic parameters) and safety (e.g., weight and hypoglycaemia) of treatment with…
- Trial name
- NCT01243424
- Testing
- linagliptin, glimepiride
- Where
- 613 sites in United States, Argentina and 41 more
- Volunteers
- 6,103 people
- Sponsor
- Boehringer Ingelheim
Cardiovascular Risk Factor, Cardiovascular Diseases
Substituting Sitting With Standing and Walking in Free-living Conditions Improves Daily Glucose Profile in South Asians
The purpose of this study is to investigate the effects of substituting sitting under free-living conditions in South Asian adults with overweight and obesity on continuous glucose profiles.
- Conditions
- Cardiovascular Risk Factor, Cardiovascular Diseases, Diabetes, Type 2 Diabetes
- Trial name
- NCT04645875
- Testing
- SIT regimen, SITless regimen
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Bedfordshire
Overweight and Obesity, Eating Behavior
Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM
The current project applies an integrative three-prong approach to investigate the potential of the dopamine D2 receptor (DRD2) agonist bromocriptine to: 1) increase homeostatic satiation signaling, 2) alter neural circuitry to…
- Trial name
- NCT05405244
- Testing
- Bromocriptine-QR
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Type 2 Diabetes, Cardiac Disease
Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk
We will use the target trial framework for causal inference to conduct this observational retrospective cohort study that uses claims data of adults with type 2 diabetes (T2D) included in the de-identified datasets of OptumLabs…
- Trial name
- NCT05214573
- Testing
- Glucagon like peptide 1 receptor agonist, Sodium-glucose cotransporter 2 inhibitor, Dipeptidyl Peptidase 4 Inhibitor
- Where
- United States
- Volunteers
- 386,301 people
- Sponsor
- Mayo Clinic
Pharmacological Action
Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients
Sitagliptin, through its effects on sensitizing alpha-cell sensitivity to glucose, can initiate counter-regulatory glucagon responses at higher glycemic thresholds, thus reducing the number of clinically apparent hypoglycemic…
- Trial name
- NCT03359590
- Testing
- Sitagliptin 100 mg
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Type 2 Diabetes, Cardiovascular Disease
Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease
The purpose of this study is to demonstrate no excess risk of cardiovascular (CV) composite events exists following long term treatment with TAK-875 compared with placebo.
- Trial name
- NCT01609582
- Testing
- TAK-875
- Where
- 584 sites in United States, Argentina and 30 more
- Volunteers
- 3,207 people
- Sponsor
- Takeda
Overweight and Obesity, PreDiabetes
Continuous Glucose Monitors (CGM) for Type 2 Diabetes (T2D) Risk Evaluation
The purpose of this research study is to determine whether continuous glucose monitors (CGM) are a safe, effective, and acceptable way to evaluate type 2 diabetes risk in youth as compared to the standard 2-hour oral glucose…
- Conditions
- Overweight and Obesity, PreDiabetes, Insulin Resistance
- Trial name
- NCT05404711
- Testing
- CGM
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mary Ellen Vajravelu, MD
Type 2 Diabetes Mellitus
Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes
This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide and insulin glargine (Lantus® injection) on beta-cell function in patients with type 2 diabetes mellitus using metformin.
- Trial name
- NCT00097500
- Testing
- exenatide, Insulin glargine, Metformin
- Where
- 3 sites in Finland, Netherlands and 1 more
- Volunteers
- 69 people
- Sponsor
- AstraZeneca
Diabetes Mellitus
Study of Raisins Versus Alternative Snacks in Patients With Type 2 Diabetes Mellitus
The objective of this study is to compare the effects of Raisins three times per day versus alternative snacks three times per day on blood sugar control and cardiovascular risk factors (weight, waist circumference, blood…
- Trial name
- NCT01677936
- Testing
- Raisins, Snacks
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Louisville Metabolic and Atherosclerosis Research Center
Obesity, Cardiovascular Risk Factor
Coordinating Pragmatic Primary Care Population Management for Obesity
The C3PO pilot and feasibility study uses a rigorous, mixed-method research design to provide information needed to refine and implement a technology-mediated primary care outreach intervention approach before conducting a larger…
- Trial name
- C3PO (NCT03998046)
- Testing
- Outreach Support for Weight Loss Goal Setting and Self-Weighing, Outreach Decision Support to Encourage Linkages to Intensive Community Lifestyle Interventions, Adaptive Tailoring of Information Delivery and Intensity of Primary Care Outreach Support
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Northwestern University
Cardiovascular Disease, High Cardiovascular Risk
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk factors.
- Conditions
- Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight
- Trial name
- CAMELLIA-TIMI (NCT02019264)
- Testing
- Lorcaserin hydrochloride
- Where
- 499 sites in United States, Australia and 6 more
- Volunteers
- 14,673 people
- Sponsor
- Eisai Inc.
Pre-diabetes, Older Adults
Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.
The goal of this study is to evaluate the hypothesis that the addition of liraglutide, a long-acting glucagon-like peptide 1 (GLP-1) analogue, to a calorie-restricted diet will lead to greater weight loss than will a…
- Trial name
- NCT01784965
- Testing
- liraglutide
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Stanford University